港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

派格生物醫藥-B

20.240

+3.37019.98%

成交量：105.91萬

成交額：2,039.15萬

市值：78.12億

市盈率：-23.98

高：20.380

開：16.870

低：16.870

收：16.870

52周最高：20.380

52周最低：8.680

股本：3.86億

香港流通股本：2.79億

量比：2.94

換手率：0.38%

股息：- -

股息率：- -

每股收益(LYR):-0.844

淨資產收益率：-224.15%

總資產收益率：-61.30%

市淨率：136.95

市盈率(LYR):-23.98

市銷率: - -

資料載入中...

總覽公司新聞公告

中泰國際助力減重療法概念股－“派格生物醫藥”（2565.HK）成功上市！

中泰金融国际

異動解讀 | 派格生物醫藥-B上市首日暴跌15%，開盤即破發

異動解讀 | 派格生物醫藥-B上市首日遭遇破發，盤中大跌15%

9輪融資、眾多頭部機構加持，減肥藥明星企業今日IPO

新股定價 | 派格生物醫藥每股定價15.6港元，公開發售獲743.78倍認購，一手中籤率8%

老虎资讯综合

港股IPO動態：今日派格生物醫藥-B、吉宏股份上市

派格生物醫藥-B香港公開發售獲743.78倍認購，發售價為每股15.6港元

老虎暗盤｜派格生物醫藥-B跌近4%，中籤一手虧300港元

老虎资讯综合

派格生物醫藥開啓申購，將於5月27日上市，募資約3億港元

一週IPO觀察：寧王、恆瑞申購踴躍，綠茶破發且綠鞋用盡，手回集團過訊

财经自媒体

新股招股 | 派格生物醫藥-B今起招股，一手入場費約7878.66港元

老虎资讯综合

派格生物醫藥擬全球發售1928.35萬股，引入益澤康瑞作為基石投資者

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02565/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物醫藥-B","latestPrice":20.24,"timestamp":1755072505715,"preClose":16.87,"halted":0,"volume":1059100,"delay":0,"floatShares":279164339,"shares":385955532,"eps":-0.8440170323180782,"marketStatus":"未開盤","change":3.37,"latestTime":"08-13 16:08:25","open":16.87,"high":20.38,"low":16.87,"amount":20391476,"amplitude":0.208062,"askPrice":20.26,"askSize":2500,"bidPrice":20.22,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.8440170323180782,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1755135000000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":16.87,"openAndCloseTimeList":[[1755048600000,1755057600000],[1755061200000,1755072000000]],"volumeRatio":2.936235,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":279164339,"roa":"-61.30%","roe":"-224.15%","lyrEps":-0.844017,"volumeRatio":2.936235,"shares":385955532,"dividePrice":0,"high":20.38,"amplitude":0.208062,"preClose":16.87,"low":16.87,"week52Low":8.68,"pbRate":"136.95","week52High":20.38,"institutionHeld":0,"latestPrice":20.24,"committee":-0.666667,"eps":-0.8440170323180782,"divideRate":0,"volume":1059100,"delay":0,"ttmEps":-0.8440170323180782,"open":16.87,"prevYearClose":15.6,"prevWeekClose":16.45,"prevMonthClose":15.36,"prevQuarterClose":10,"fiveDayClose":15.37,"twentyDayClose":13.04,"sixtyDayClose":15.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2025-08-12","current":-21.042303,"percent":0.018182,"low":-22.018639,"twenty":-19.070122,"median":-13.169126,"eighty":-11.474906,"high":-11.114373,"avg":-14.861701,"sd":3.397368,"marketCap":6511069824},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-12","current":-21.042303,"twenty":-19.070122,"median":-13.169126,"eighty":-11.474906,"marketCap":6511069824}],"updateTime":1755112574001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538435278","title":"中泰國際助力減重療法概念股－“派格生物醫藥”（2565.HK）成功上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2538435278","media":"中泰金融国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538435278?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 09:48","pubTimestamp":1748310532,"startTime":"0","endTime":"0","summary":"中泰国际作为联席账簿管理人及联席牵头经办人的项目，减重疗法概念股 –派格生物医药( 杭州) 股份有限公司于2025年5月27日成功上市。派格生物医药本次全球发行约1928.35万股H股，定价为每股H股15.60港元，集资总额约3.01亿港元。派格生物医药( 杭州) 股份有限公司派格生物医药，成立于2008年，作为一家专注于自主研究及开发慢性病创新疗法的生物技术公司，重点关注代谢紊乱领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527122532a48dc544&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527122532a48dc544&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"1125211878","title":"異動解讀 | 派格生物醫藥-B上市首日暴跌15%，開盤即破發","url":"https://stock-news.laohu8.com/highlight/detail?id=1125211878","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125211878?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 09:32","pubTimestamp":1748309561,"startTime":"0","endTime":"0","summary":"5月27日，新上市的派格生物医药-B股价表现不佳，盘中大跌15%，引发市场关注。该公司今日在港交所挂牌上市，但开盘即告破发，开盘价为13港元，较发行价15.6港元下跌16.67%。尽管公开发售反应热烈，但派格生物医药-B上市首日的股价表现却令投资者失望。作为一家专注于慢性病创新疗法研发的生物科技公司，派格生物医药-B的核心产品PB-119虽已接近商业化阶段，但投资者可能需要更多时间来评估公司的长期发展前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"1116268702","title":"異動解讀 | 派格生物醫藥-B上市首日遭遇破發，盤中大跌15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116268702","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116268702?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 09:32","pubTimestamp":1748309550,"startTime":"0","endTime":"0","summary":"港股新上市公司派格生物医药-B今日迎来挂牌首日，却遭遇\"开门黑\"。该股在交易时段内大跌15%，引发市场关注。派格生物医药-B此前公布的招股结果显示，公司IPO定价为每股15.6港元，公开发售部分获得743.78倍超额认购，一手中签率仅为8%。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"2538348603","title":"9輪融資、眾多頭部機構加持，減肥藥明星企業今日IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2538348603","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538348603?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 08:09","pubTimestamp":1748304549,"startTime":"0","endTime":"0","summary":"在火热的T2DM及减肥赛道，派格生物是一级市场的明星项目。招股书显示，在IPO之前，派格生物于2008年至2023年之间先后获得9轮融资，投资方包括元生创投、泰格医药、盈科资本、前海、君联资本等一众知名机构与企业。初步研究结果表明，PB-718可减少肝脏中的脂质积累，从而防止肝脏炎症和随后出现的肝纤维化。截至2025年2月，国内已有15款用于治疗T2DM的GLP-1药物，以及6款用于肥胖症的药物。此外，也有GLP-1减重药物将医美机构纳入营销网络。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527081209a6ee13e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527081209a6ee13e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","03347","BK1583","BK1141","BK1576"],"gpt_icon":1},{"id":"1146090593","title":"新股定價 | 派格生物醫藥每股定價15.6港元，公開發售獲743.78倍認購，一手中籤率8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146090593","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146090593?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 08:05","pubTimestamp":1748304305,"startTime":"0","endTime":"0","summary":" $派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"派格生物医药每股定价15.6港元，公开发售超购742倍，一手中签率8%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0},{"id":"2538483695","title":"港股IPO動態：今日派格生物醫藥-B、吉宏股份上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2538483695","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538483695?lang=zh_tw&edition=fundamental","pubTime":"2025-05-27 06:06","pubTimestamp":1748297201,"startTime":"0","endTime":"0","summary":"格隆汇5月27日｜今日派格生物医药-B(2565.HK)、吉宏股份(2603.HK)上市，手回集团(2621.HK)处于申购期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527060705976655f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527060705976655f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","HSTECH","02603","02565"],"gpt_icon":0},{"id":"2538056551","title":"派格生物醫藥-B香港公開發售獲743.78倍認購，發售價為每股15.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538056551","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538056551?lang=zh_tw&edition=fundamental","pubTime":"2025-05-26 20:07","pubTimestamp":1748261268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)公布配发结果，全球发售项下发售1918.35万股，其中香港公开发售的发售股份数目为964.2万股，国际发售的发售股份数目为964.15万股;最终发售价为每股15.6港元，全球发售净筹约2.32亿港元，每手500股，预期H股将于香港时间2025年5月27日(星期二)上午九时正开始在联交所买卖。其中，香港公开发售获743.78倍认购，国际发售获1.13倍认购。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1297723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","161726","02565"],"gpt_icon":0},{"id":"1125385100","title":"老虎暗盤｜派格生物醫藥-B跌近4%，中籤一手虧300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125385100","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125385100?lang=zh_tw&edition=fundamental","pubTime":"2025-05-26 16:15","pubTimestamp":1748247330,"startTime":"0","endTime":"0","summary":"5月26日，$派格生物医药-B$暗盘跌近4%，报15港元/股，中签一手亏300港元；公司每股定价15.6港元，每手500股，将于5月27日（周二）正式挂牌交易。PB-119主要用于T2DM及肥胖症一线治疗。按发售价为每股H股15.60港元计算，全球发售总净所得款项约为2.318亿港元。杭州拱墅是一家于2018年在中国成立的有限公司。其已投资超过30家公司，总投资额超过人民币25亿元。杭州拱墅已同意就基石投资者认购基石配售项下的发售股份担任其担保人。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2619d86031d9f015a3a3bab995ddbeb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":1},{"id":"2537464418","title":"派格生物醫藥開啓申購，將於5月27日上市，募資約3億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537464418","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537464418?lang=zh_tw&edition=fundamental","pubTime":"2025-05-20 09:04","pubTimestamp":1747703053,"startTime":"0","endTime":"0","summary":"公告显示，派格生物于5月19日至5月22日招股，预计将于2025年5月27日在港交所上市。本次上市，派格生物拟全球发售1928.35万股，无超额配售权，发售价为每股15.60港元。据此计算，派格生物的募资总额约3.01亿港元，募资净额约2.32亿港元。2023年和2024年，派格生物分别取得其他净收入约人民币1463.5万元和700.7万元，年内亏损分别约2.79亿元、2.83亿元。但在派格生物2025年4月28日披露的招股书中，苏州派格的注册资本仍是100万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520092041a484b045&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520092041a484b045&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"2536960524","title":"一週IPO觀察：寧王、恆瑞申購踴躍，綠茶破發且綠鞋用盡，手回集團過訊","url":"https://stock-news.laohu8.com/highlight/detail?id=2536960524","media":"财经自媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536960524?lang=zh_tw&edition=fundamental","pubTime":"2025-05-19 11:27","pubTimestamp":1747625220,"startTime":"0","endTime":"0","summary":"港股IPO观察截止2025年的第20周，港交所3家新股上市，1家招股，3家通过聆讯，8家递交招股书。首日大跌12%，招银国际为稳价人，绿鞋已基本用完。本次IPO每股发售价23.30港元，计划全球发售4662万股，无超额配股权。手回集团通过IPO聆讯5月15日，小雨伞保险的母公司深圳手回集团在港交所披露聆讯后的招股书，或很快在香港主板IPO上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-19/doc-inexakse3019512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02629","LU0370786039.SGD","ARAI","600276","BK0183","LU0345780521.USD","02899","BK1198","ADC","BK0188","LU0405327494.USD","LHAI","LU0828237940.HKD","BK4231","LU0345780281.USD","LU1504937902.USD","LU2097828805.USD","DLHZ","FMFC","HK0000320223.HKD","RNBW","LAWR","LU2097828714.EUR","LU1969619763.USD","BK4023","LU0886674414.USD","BK1544","LU1064130708.USD","RNA","01276","ETOR","LU1720050803.USD","EGG","FTRK","LU1328615791.USD","02565","LU0572944931.SGD","02603","BK4080","HK0000306701.USD","OMSE","HSPO","MSGY","BK4585","LU1251922891.USD","LU0096374516.USD","03750"],"gpt_icon":1},{"id":"2536123165","title":"新股招股 | 派格生物醫藥-B今起招股，一手入場費約7878.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536123165","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536123165?lang=zh_tw&edition=fundamental","pubTime":"2025-05-19 07:42","pubTimestamp":1747611775,"startTime":"0","endTime":"0","summary":"5月19日，派格生物医药-B于2025年5月19日-5月22日招股，拟全球发售1928.35万股，香港公开发售占10%，国际发售占90%。发售价将为每股发售股份15.60港元，每手500股，预期H股将于2025年5月27日上市。申购阶梯：每手500股，入场费7878.66港元。乙组门槛为35万股，申购所需资金约551.51万港元。按发售价为每股H股15.60港元计算，全球发售总净所得款项约为2.318亿港元。杭州拱墅已同意就基石投资者认购基石配售项下的发售股份担任其担保人。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1294537.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新股招股 | 派格生物医药-B今起招股，一手入场费约7878.66港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":1},{"id":"2536512485","title":"派格生物醫藥擬全球發售1928.35萬股，引入益澤康瑞作為基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2536512485","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536512485?lang=zh_tw&edition=fundamental","pubTime":"2025-05-19 07:12","pubTimestamp":1747609920,"startTime":"0","endTime":"0","summary":"派格生物医药-B于2025年5月19日-5月22日招股，拟全球发售1928.35万股，香港公开发售占10%，国际发售占90%。PB-119主要用于T2DM及肥胖症一线治疗。按发售价为每股H股15.60港元计算，全球发售总净所得款项约为2.318亿港元。杭州拱墅是一家于2018年在中国成立的有限公司。杭州拱墅的控股公司拱墅投资主要从事生物科技及医疗等多个行业的股权投资。杭州拱墅已同意就基石投资者认购基石配售项下的发售股份担任其担保人。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-19/doc-inewzyaf1251270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161726","02565"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":52,"code":"91000000","status":"200"}]}}